Trials / Completed
CompletedNCT01332487
Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,068 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This retrospective study aims to assess the impact of early vs delayed 5-alpha-reductase inhibitor (5ARI) therapy in patients with BPH on alpha-blocker (AB) therapy and the risk of acute urinary retention (AUR), prostate-related surgery, and emergency surgery (defined as prostate surgery occurring within 30 days of AUR). The MarketScan database will be utilized for this study (2000-2008).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5ARI + AB | 5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2011-04-11
- Last updated
- 2017-06-19
- Results posted
- 2012-02-29
Source: ClinicalTrials.gov record NCT01332487. Inclusion in this directory is not an endorsement.